AI-powered CT help to guide pneumonia care

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pragmatic, multicenter randomized trial compares usual pneumonia care with or without an AI-generated CT report that characterizes likely pathogens, lung involvement, and deterioration risk. Clinicians review the AI output with imaging and patient data, but remain responsible for tests and treatment. The study uses 1:1 randomization and blinded outcome adjudication, enrolling patients early in their pneumonia episode before major organ support is needed. Primary outcomes focus on mortality and new invasive respiratory or circulatory support within 28 days, with follow-up through day 90 after discharge. Secondary considerations include how the AI report influences testing, antimicrobial choices, and monitoring, as well as technical diagnostic performance.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Hospitalized with suspected or confirmed pneumonia and new or progressive infection-compatible chest CT abnormalities.
2. At increased clinical risk: new or increased oxygen requirement above the stable pre-illness baseline attributable to the current pneumonia, OR protocol-defined immunocompromise.
3. A clinically indicated CT meeting the frozen input-quality criteria is available. Randomize within 24 hours after that CT and within 48 hours of documented recognition of the current pneumonia episode.
4. No primary qualifying organ support earlier in the current episode, at baseline, or already clinically indicated before allocation.
5. Written informed consent from the participant or an authorized representative before randomization.

Exclusion Criteria:

1. No interpretable CT suitable for the locked model; a noninfectious diagnosis fully explains the findings without suspected concomitant pneumonia.
2. Qualifying invasive respiratory or circulatory support in the current episode, including support already clinically indicated even if not yet delivered.
3. Previous randomization in this trial; a concurrent interventional study that conflicts with the AI care strategy.
4. Known pregnancy, outside the initial intended-use population; breastfeeding alone is not an exclusion.
5. Exclusive comfort-focused care or a pre-existing ceiling of care that rules out both invasive ventilation and vasopressor support.
6. Consent cannot be obtained under the approved arrangements.

Where it's running

• Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
  Wuhan, Hubei, China Recruiting

Study contacts

• Study coordinator: Xiaoyu Han
• Email: xiaoyuhan1123@163.com
• Phone: +8618202771604

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Respiratory Physiotherapy in Critically Ill Pneumonia Patients

  This study tests whether a structured breathing and chest therapy program can change inflammatory biomarkers in adults with pneumonia in the ICU compared to usual care.

  Recruiting Hospital H+ Queretaro · Querétaro · NCT07909616

• Wintergreen oil inhalation for shortness of breath in pneumonia patients

  Hospitals will test whether inhaling wintergreen essential oil helps relieve dyspnea in adults with pneumonia.

  Recruiting Far Eastern Memorial Hospital · New Taipei City, Taipei · NCT07894835

• Optimising Antibiotic Use for Paediatric LRTIs in Africa

  This study tests whether using point-of-care CRP tests together with the PREPARE score can safely reduce antibiotic use in infants aged 2–24 months with lower respiratory infections in a Johannesburg hospital.

  Recruiting University of Witwatersrand, South Africa · Johannesburg, Gauteng · NCT07841691

• Buteyko Breathing vs Incentive Spirometry for Smog-Induced Pneumonia

  We’re testing whether the Buteyko Breathing Technique can improve oxygen levels and breathe easier for adults with smog-related pneumonia compared to incentive spirometry.

  Recruiting Lahore University of Biological and Applied Sciences · Lahore, Punjab Province · NCT07759583

• FUNGAL-P: A score to spot fungal pneumonia early in adults with pneumonia

  Aimed at adults with pneumonia, this study tests a new score to help identify fungal pneumonia sooner so doctors can test appropriately and start antifungal treatment when needed.

  Recruiting Azienda Ospedaliero-Universitaria Careggi · Florence · NCT07681583

• AgenT-797 plus standard care in severe pneumonia with acute hypoxemic respiratory failure

  We are testing whether a single IV dose of agenT-797 added to standard care can reduce short-term death in adults with severe pneumonia and moderate to severe AHRF.

  Recruiting Phase 2 MiNK Therapeutics · San Francisco, California and 3 other locations · NCT07615010

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.